CSI Market
Sign In | Register

Damora Therapeutics Inc (DMRA) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access DMRA Annual Income Statement →
The income statement data below highlights shifts in Damora Therapeutics Inc's operating performance over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
Q2 2026 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing9.45
Depreciation & Amortization0.00
Research and Development Expense25.54
Other Operating Expense / -Income0.00
Total operating costs including COS34.99
Operating income / -loss-34.99
Interest Expense0.00
Net Interest Expense / -Income0.00
Foreign Currency Transaction Gain (Loss), before Tax0.02
Other loss / -income0.00
Total costs & expenses0.00
Income & Taxes
Income / -loss before income taxes-30.92
Income taxes expenses / -benefit0.26
Income after income taxes-31.17
Income / -loss from continuing operations-31.20
Net income / -loss-31.20
Income / -loss to shareholder-31.17
EBIT-30.92
EBITD-30.91
EBITDA-30.91
Earnings Per Share
Basic EPS (excl. extra items)-0.39
Basic Net EPS-0.39
Basic shares outstanding (Mill. of Units)61.12
Diluted Net EPS-0.39
Diluted average shares (Mill. of Units)61.12
4 historic quarters locked

Sign in to unlock the full Damora Therapeutics Inc income statement history.

Sign In Create Free Account

About Damora Therapeutics Inc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: August 10, 2026
  • Original filing: dmra-20260630.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.